Cancer Moonshot℠

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

The Beau Biden Cancer Moonshot to accelerate cancer research aims to make more therapies available to more patients, while also improving our ability to prevent cancer and detect it at an early stage.

To ensure that the Cancer Moonshot's goals and approaches are grounded in the best science, a Cancer Moonshot Task Force consulted with external experts, including the presidentially appointed National Cancer Advisory Board (NCAB).

A Blue Ribbon Panel of experts was established as a working group of the NCAB to assist the board in providing this advice. The panel's charge was to provide expert advice on the vision, proposed scientific goals, and implementation of the Cancer Moonshot.

Congress passed the 21st Century Cures Act in December 2016 authorizing $1.8 billion in funding for the Cancer Moonshot over 7 years. An initial $300 million has been appropriated in fiscal year (FY) 2017 to fund Moonshot initiatives.

Blue Ribbon Panel

The Blue Ribbon Panel (BRP) outlined 10 research recommendations to accelerate progress against cancer. Learn about the panel and its report.

Cancer Moonshot℠ Implementation

Implementation teams are considering multiple ways to fund new programs as well as expansions of ongoing efforts to advance the goals of the Cancer Moonshot.

Funding Opportunities to Support Cancer Moonshot Priorities

NCI is accepting applications for research grants that align with the goals of the Cancer Moonshot.

Most text on the National Cancer Institute website may be reproduced or reused freely. The National Cancer Institute should be credited as the source. Please note that blog posts that are written by individuals from outside the government may be owned by the writer, and graphics may be owned by their creator. In such cases, it is necessary to contact the writer, artist, or publisher to obtain permission for reuse.

We welcome your comments on this post. All comments must follow our comment policy.